46% of patients identified as high risk for recurrence according Read More
The PRospective study Of MammaPrint in breast cancer patients with Read More
Company also announces new ASCO data presentation from the prospective Read More
News, videos, social media and more about the recently released Read More
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 Read More
Company will also host a lunch symposium on genomic assays Read More
Agendia is disappointed with the recent update to the American Read More
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
Fax: (844) 711-9132
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2026 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
